SHIFT AI Newsroom · GLOBAL
Enobosarm Enters Proof-of-Concept Study for Weight Loss
A proof-of-concept study has been registered to evaluate the effects of Enobosarm on total body weight, physical function, and safety in patients treated with a GLP-1 receptor agonist for weight loss.
A proof-of-concept study has been registered to investigate the effects of Enobosarm on total body weight, physical function, and safety in patients treated with a GLP-1 receptor agonist for weight loss. The study is currently in the proof-of-concept stage, and its results may provide insight into the potential use of Enobosarm for weight loss.
What this means in the UK
This study may provide insight into the potential use of Enobosarm for weight loss in the UK, but its current status is limited to a proof-of-concept study and its availability and approval in the UK are unknown.
Known facts
- A proof-of-concept study evaluating Enobosarm in patients treated with a GLP-1 receptor agonist for weight loss has been registered.